Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The High-affinity immunoglobulin epsilon receptor-Immunoglobulin E-Allergen complex is the central molecular assembly that mediates acute allergic responses to Hymenoptera venom. This complex is formed when multivalent venom allergens, such as phospholipase A1 (Api m 1) or antigen 5 (Ves v 5), cross-link IgE antibodies that are already bound to the alpha subunit of the FcεRI receptor on mast cells and basophils [Gould & Sutton, Nature Reviews Immunology, 2008; Sutton et al., Annual Review of Immunology, 2019]. This cross-linking event triggers an intracellular signaling cascade involving kinases like Lyn and Syk, leading to the rapid degranulation and release of inflammatory mediators such as histamine and leukotrienes [Siraganian, Nature Reviews Immunology, 2003; Krystal, Journal of Allergy and Clinical Immunology, 2000]. In sensitized individuals, this process can escalate into life-threatening systemic anaphylaxis [Bilò et al., Allergy, 2005]. Therapeutic strategies primarily focus on disrupting this complex; for instance, the monoclonal antibody Omalizumab binds to the Fc region of free IgE, preventing its attachment to FcεRI and thus inhibiting the formation of the recognition complex [Normansell et al., Cochrane Database of Systematic Reviews, 2014]. Furthermore, venom immunotherapy (VIT) works by inducing "blocking" IgG4 antibodies that compete with IgE for allergen binding, effectively neutralizing the allergens before they can activate the receptor complex [Sturm et al., Allergy, 2018].
Inhibition of the interaction between free IgE and the high-affinity IgE receptor (FcεRI) on effector cells, thereby preventing the formation of the allergen-IgE-FcεRI complex and subsequent cellular activation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High-affinity immunoglobulin epsilon receptor-Immunoglobulin E-Allergen complex (FcεRI-IgE-Allergen complex).